🔎 Trials Near Me

Home › Linfoma di Burkitt › Colorado

Studi clinici su Linfoma di Burkitt nello stato di Colorado

13 studi su Linfoma di Burkitt cercano partecipanti presso sedi nello stato di Colorado.

Città nello stato di Colorado

Testo ufficiale dello studio (inglese)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's Hospital Colorado, Aurora
In reclutamentoFase 2
366 Days – 46 Years · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06124157

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Hospital Colorado, Aurora
In reclutamentoStudio osservazionale
Età da 0 a 38 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06131801

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Children's Hospital Colorado, Aurora
In reclutamentoFase 2
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • CBCI, Colorado Blood Cancer Institute, Denver
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07648264

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
In reclutamentoFase 1/2
6 Months – 25 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06395103

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

  • Children's Hospital Colorado, Aurora
In reclutamentoFase 1/2
31 Days – 30 Years · Tutti i sessi · Aggiornato il 14 set 2026 · NCT04544592

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's Hospital Colorado, Aurora
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
In reclutamentoFase 2
Età da 1 a 30 · Tutti i sessi · Aggiornato il 1 set 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Children's Hospital Colorado, Aurora
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
In reclutamentoFase 3
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Colorado Children's Hospital, Denver
In reclutamentoFase 2
Età da 7 a 25 · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05082519

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Colorado Blood Cancer Institute, Denver
In reclutamentoFase 1/2
Età da 13 a 90 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT06533579

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

  • Children's Hospital Colorado, Aurora
In reclutamentoFase 1
3 Months – 30 Years · Tutti i sessi · Aggiornato il 28 nov 2025 · NCT06559189

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

  • University of Colorado - Aurora Cancer Center, Aurora
  • Sarah Cannon - Colorado Blood Cancer Institute, Denver
In reclutamentoFase 1/2
Età da 15 a 50 · Tutti i sessi · Aggiornato il 9 set 2025 · NCT04150497

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • Children's Hospital Colorado, Aurora
In reclutamentoFase 2
Età da 1 a 25 · Tutti i sessi · Aggiornato il 4 mag 2025 · NCT03509961

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.